Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Dear Editor,

We read with interest the recent article of Alexopoulos et al. [1], and we would like to express our (partially divergent) opinion on the critical matter of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological testing.

Although it seems at least theoretically agreeable that serological assessment may be useful for defining potential incidence and prevalence of community infections (i.e., “seropositivity”), and thus for driving public health policies, this concept seems no longer so straightforward after the surge of the new Omicron sublineages as it was during the periods of prevalence of the former SARS-CoV-2 variants. This conclusion is based on some important analytical and biological issues that we have summarized in Table 1.

First, the currently available immunoassays have been manufactured using antigen(s) derived from the prototype (ancestral) SARS-CoV-2 strain identified and sequenced in Wuhan, in 2019 [2]. Since then, the viral genome has undergone such a huge number of mutations, that the identity of the epitopes used to construct the immunoassays no longer reflects that of the circulating variants. The serum levels of anti-SARS-CoV-2 antibodies may thus be variably underestimated, up to the point that some anti-SARS-CoV-2 immunoassays are no longer capable to detect antibodies generated against the most recent circulating Omicron sublineages (e.g., BA.4/5, BA.2.75 and BA.2.75.2, BA.4.6, BQ.1 and BQ.1.1, BF.7, XBB.1 and so forth) as recently shown by two independent studies [3,4]. These aspects are also crucial when assessing vaccine response by serology in selected populations, as endorsed by Alexopoulos et al. [1]. In fact, the neutralizing potential versus Omicron sublineages of antibodies developed after monovalent COVID-19 vaccination is no longer adequately reflected by the anti-SARS-CoV-2 serum levels measured by some commercial immunoassays [4]. For this purpose, plaque reduction neutralization tests and/or live virus micro-neutralization assays are obviously preferable [5].

The progressive waning of natural and vaccine-elicted immunity is another important drawback, in that anti-SARS-CoV-2 antibodies, targeting both the spike and nucleocapsid proteins, become no longer detectable in the vast majority of subjects between 12 and 24 months from previous SARS-CoV-2 infection or COVID-19 vaccination [6,7]. Thus, testing negative (i.e., being “seronegative”) during SARS-CoV-2 serological surveys does not always mirror the lack of infection or ineffective vaccination, in that anti-SARS-CoV-2 antibodies may have already waned to undetectable levels, whilst cellular immunity will persist for longer and will also more efficiently protect from the risk of developing severe COVID-19 illness [8]. Finally, both harmonization and standardization of infectious disease serology are largely unmet targets [9], thus precluding the possibility to compare or pool measures of anti-SARS-CoV-2 antibodies obtained in different clinical laboratories, using different methods, irrespective of the availability of new international standards such as the WHO 21/338. To this end, only anti-SARS-CoV-2 immunoassays showing good concordance with neutralization tests performed with live virus should be used for epidemiological surveys and clinical practice [10].

In conclusion, although we would agree that serological testing has many theoretical advantages, the currently available anti-SARS-CoV-2 commercial immunoassays appear mostly outdated and poorly harmonized (standardization remains a chimera), and should hence be considered presently unfit for achieving most of the goals for which they have been originally designed and commercialized.

Declaration of Competing Interest

The authors declare they have no conflict of interest.

References

[1] Alexopoulos H, Trougakos IP, Dimopoulos MA, Terpos E. Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies. Eur J Intern Med 2022.
[2] Lippi G, Adeli K, Plebani M. Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants. Clin Chem Lab Med 2021.
[3] Springer DN, Perkmann T, Jasti CM, Mach P, Prüger K, Marculescu R, et al. Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant. Microbiol Spectr 2022;10(5):e021922.
[4] Favresse J, Gillot C, Bayart JL, David C, Simon G, Wauthier L, et al. Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. J Med Virol 2022.
[5] Lippi G, Plebani M. The presence of anti-SARS-CoV-2 antibodies does not necessarily reflect efficient neutralization. Int J Infect Dis 2022;117:24.
[6] Pelleas S, Woudenberg T, Rosado J, Donnadieu F, Garcia L, Obadia T, et al. Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response.
and Serological Estimation of Time Since Infection. J Infect Dis 2021;224(9):1489–90.

[7] Salvagno GL, Henry BM, Pighi L, De Nito S, Gianfilippi G, Lippi G. The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals six months after BNT162b2 vaccination is consistent with the need for vaccine boosters. Clin Chem Lab Med 2021;60(2):e29–31.

[8] Lippi G, Mattiuzzi C, Henry BM. Is cellular immunity the future key for deciphering and monitoring COVID-19 vaccines efficacy? J Lab Precis Med 2022;7:18.

[9] Plebani M, Lippi G. Standardization and harmonization in laboratory medicine: not only for clinical chemistry measurands. Clin Chem Lab Med 2022.

[10] Padoan A, Bondante F, Pogliari M, Bortolami A, Negrié D, Zuin S, et al. Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity. EBioMedicine 2020;62:103101.

Giuseppe Lippi\textsuperscript{a\*}, Mario Plebani\textsuperscript{b}

\textsuperscript{a} Section of Clinical Biochemistry and School of Medicine, University of Verona, Verona, Italy

\textsuperscript{b} University of Padova, Padova, Italy

\* Corresponding author at: Section of Clinical Biochemistry, University Hospital of Verona, Piazzale LA Scuro, 37134 Verona, Italy.

E-mail address: giuseppe.lippi@univr.it (G. Lippi).